Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note released on Wednesday. The firm issued a hold rating on the medical research company’s stock.

Separately, D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Cytosorbents in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Price Performance

Shares of NASDAQ:CTSO opened at $1.00 on Wednesday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The company has a market cap of $54.68 million, a PE ratio of -2.78 and a beta of 0.78. The firm has a 50 day simple moving average of $1.07 and a 200 day simple moving average of $1.05. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61.

Institutional Investors Weigh In On Cytosorbents

Several institutional investors and hedge funds have recently made changes to their positions in CTSO. Millennium Management LLC bought a new position in Cytosorbents in the 4th quarter valued at $30,000. Northern Trust Corp boosted its position in shares of Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after purchasing an additional 16,701 shares in the last quarter. Avenir Corp lifted its stake in Cytosorbents by 4.0% in the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock valued at $2,815,000 after buying an additional 118,387 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Cytosorbents in the 4th quarter worth $99,000. Finally, Renaissance Technologies LLC boosted its position in shares of Cytosorbents by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after buying an additional 8,400 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.